ArrowMark Partners

Type

Private equity

Status

Active

Location

Denver, United States

Total investments

59

Average round size

116M

Portfolio companies

43

Rounds per year

3.47

Lead investments

5

Follow on index

0.24

Exits

18

Stages of investment
Late Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

ArrowMark Partners is the famous VC, which was founded in 2007. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Denver.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Twilio, Orchard Therapeutics. Among the most successful fund investment fields, there are SMS, Medical. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this ArrowMark Partners performs on 6 percentage points more the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2018. The typical startup value when the investment from ArrowMark Partners is more than 1 billion dollars.

We also calculated 2 valuable employees in our database.

The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the ArrowMark Partners, startups are often financed by F-Prime Capital, New Enterprise Associates, Pfizer Venture Investments. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, RA Capital Management, OrbiMed. In the next rounds fund is usually obtained by The Durst Organization Inc., Elysium Capital Management, Stratim Capital.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
59
Lead investments
5
Exits
18
Rounds per year
3.47
Follow on index
0.24
Investments by industry
  • Biotechnology (41)
  • Health Care (19)
  • Pharmaceutical (16)
  • Therapeutics (11)
  • Medical (10)
  • Show 63 more
Investments by region
  • United States (53)
  • Bermuda (1)
  • China (1)
  • United Kingdom (1)
Peak activity year
2018
Number of Unicorns
5
Number of Decacorns
5
Number of Minotaurs
4

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
355M
Group Appearance index
1.00
Avg. company exit year
8
Avg. multiplicator
1.64

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
ADVANO 21 Aug 2017 Energy Storage, Manufacturing, Energy, Advanced Materials, Nanotechnology Seed 120K United States, Louisiana, New Orleans
PediaQ 01 Oct 2014 Health Care, Wellness, Apps, Medical Seed 250K United States, Texas, Dallas
SmartLabs 31 Dec 2019 Biotechnology, Manufacturing, Life Science, Pharmaceutical Early Stage Venture 36M United States, Massachusetts, Boston
SmartLabs 18 Jan 2024 Biotechnology, Manufacturing, Life Science, Pharmaceutical Late Stage Venture 48M United States, Massachusetts, Boston

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.